![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg?width=800&height=600&carousel=1)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram](https://www.researchgate.net/publication/333294637/figure/fig2/AS:761410896277505@1558545912697/Kaplan-Meier-curve-showing-the-overall-survival-OS-of-the-patient-cohort-grouped-by.png)
Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram
![Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram](https://www.researchgate.net/publication/342628025/figure/fig2/AS:908830661697536@1593693523052/Kaplan-Meier-curves-for-overall-survival-OS-overall-survival-non-MDT-non.png)
Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram
![Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0805-y/MediaObjects/41416_2020_805_Fig1_HTML.png)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
![Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download](https://slideplayer.com/98/17007632/big_thumb.jpg)
Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download
![Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/cci/2019/cci.2019.3/cci.19.00013/20190809/images/large/cci.19.00013t1.jpeg)
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
![Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12890-020-01270-z/MediaObjects/12890_2020_1270_Fig4_HTML.png)
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full
![PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/eb56a0ed555af54134d5949c8b856bff15592fe4/3-Figure1-1.png)
PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5716896/bin/nihms896091f1.jpg)
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC
![Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420397969-gr2.jpg)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
![Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer](https://eau-bb-01.s3.amazonaws.com/webcasts/EAU22/1313581ca4fd152b6f8cec0b88292a11ae664b/131358/media/Slide1.jpg)
Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer
![The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ). The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).](https://s3-eu-west-1.amazonaws.com/ppreviews-plos-725668748/5038006/preview.jpg)
The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).
![A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram](https://www.researchgate.net/profile/Richard-Stephens-3/publication/5503862/figure/fig2/AS:667207130423307@1536085984764/A-Overall-survival-OS-in-elderly-patients-70-years-in-relation-to-treatment-arm.png)
A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/attachment/4c56dec5-310c-4e24-ab78-fbf95f7c8023/gr1.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/4/e002114/F2.large.jpg)